Innoviva (INVA) Other Non-Current Assets (2010 - 2026)
Innoviva posted quarterly Other Non-Current Assets of $40.5 million for Q1 2026, down 1.8% year-on-year from $41.3 million in Q1 2025, and down 0.53% on a QoQ basis from $40.7 million in Q4 2025.
Innoviva (INVA) has 17 years of Other Non-Current Assets data on file, last reported at $40.5 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 1.8% year-over-year to $40.5 million; the trailing twelve-month figure through Mar 2026 stood at $40.5 million (down 1.8% YoY), and the FY2025 full-year result was $40.7 million, down 1.77% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $40.5 million, down from $40.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $41.5 million in Q4 2024 and bottomed at $313000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $3.6 million (2023), against an average of $14.1 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets jumped 38981.82%; it then plunged 60.71% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $4.3 million in 2022, then decreased by 24.01% to $3.3 million in 2023, then soared by 1169.57% to $41.5 million in 2024, then dropped by 1.77% to $40.7 million in 2025, then declined by 0.53% to $40.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $40.5 million (Q1 2026), $40.7 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 40.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.53 Mn |
| Dec 31, 2025 | 40.74 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 41.18 Mn |
| Mar 31, 2025 | 41.27 Mn |
| Dec 31, 2024 | 41.48 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.98 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 3.27 Mn |
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Mar 31, 2023 | 3.89 Mn |
| Dec 31, 2022 | 4.30 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Mar 31, 2022 | 313,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Sep 30, 2021 | 136,000.00 |
| Jun 30, 2021 | 162,000.00 |
| Mar 31, 2021 | 188,000.00 |
| Dec 31, 2020 | 214,000.00 |
| Sep 30, 2020 | 239,000.00 |
| Jun 30, 2020 | 264,000.00 |
| Mar 31, 2020 | 288,000.00 |
| Dec 31, 2019 | 312,000.00 |
| Sep 30, 2019 | 48,000.00 |
| Jun 30, 2019 | 37,000.00 |
| Mar 31, 2019 | 37,000.00 |
| Dec 31, 2018 | 37,000.00 |
| Sep 30, 2018 | 37,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 37,000.00 |
| Dec 31, 2017 | 37,000.00 |
| Sep 30, 2017 | 37,000.00 |
| Jun 30, 2017 | 37,000.00 |
| Mar 31, 2017 | 37,000.00 |
| Dec 31, 2016 | 37,000.00 |
| Sep 30, 2016 | 40,000.00 |
| Jun 30, 2016 | 58,000.00 |
| Mar 31, 2016 | 18,000.00 |
| Dec 31, 2015 | 18,000.00 |
| Sep 30, 2015 | 15.81 Mn |
| Jun 30, 2015 | 16.57 Mn |
| Mar 31, 2015 | 17.34 Mn |
| Dec 31, 2014 | 18.10 Mn |
| Sep 30, 2014 | 19.95 Mn |
| Jun 30, 2014 | 22.39 Mn |
| Mar 31, 2014 | 833,000.00 |
| Dec 31, 2013 | 833,000.00 |
| Sep 30, 2013 | 833,000.00 |
| Jun 30, 2013 | 833,000.00 |
| Mar 31, 2013 | 833,000.00 |
| Dec 31, 2012 | 833,000.00 |
| Sep 30, 2012 | 833,000.00 |
| Jun 30, 2012 | 2.10 Mn |
| Mar 31, 2012 | 2.31 Mn |
| Dec 31, 2011 | 2.51 Mn |
| Sep 30, 2011 | 893,000.00 |
| Jun 30, 2011 | 893,000.00 |
| Dec 31, 2010 | 3.34 Mn |